<DOC>
	<DOCNO>NCT00467389</DOCNO>
	<brief_summary>The purpose study determine safety intravenous cocaine subject receive oral donepezil .</brief_summary>
	<brief_title>Use Donepezil Treatment Cocaine Dependence</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , placebo control , inpatient , single-center , parallel group evaluation potential oral donepezil attenuate cocaine-induced craving . Non-treatment-seeking cocaine-experienced volunteer receive baseline treatment intravenous cocaine ( 30Mg ) . Forty-two subject tolerate baseline cocaine infusion receive two subsequent intravenous dos cocaine double-blind treatment oral placebo 5 mg daily donepezil . Each dose cocaine precede followed administration intravenous placebo ( saline ) random order .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Nontreatment seek , experienced cocaine user , use cocaine smoke intravenous injection within four week prior screen , must supply cocainepositive urine obtain within four week entry study . Shows sign psychostimulant toxicity , history medical adverse reaction cocaine psychostimulants , include loss consciousness , chest pain , cardiac ischemia , seizure . Has current psychiatric disorder drug abuse dependence dementia . Meets Diagnostic Statistical Manual Mental DisordersIV criterion dependence opiate , benzodiazepine , alcohol , sedativehypnotics . Has receive opiatesubstitution therapy ( methadone buprenorphine ) within two month prior enrollment . Has current past history seizure disorder , include alcohol psychostimulant related seizure , family history seizure disorder . Has diagnosis adult asthma , chronic obstructive pulmonary disease , include history acute asthma within past two year , current recent ( past two year ) treatment inhaled oral betaadrenergic agonist . Has head trauma result neurological sequela . Has unstable medical condition , , judgement investigator , would make participation hazardous .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Acetylcholine</keyword>
	<keyword>Acetylcholinesterase</keyword>
	<keyword>Butyrylcholinesterase</keyword>
	<keyword>Cholinesterase Inhibitor</keyword>
</DOC>